SILAC-based quantitative proteomics analysis of lung cancer cells treated with a DNMTi drug decitabine
Ontology highlight
ABSTRACT: DNA methyltransferase inhibitors (DNMTi) has been shown to modulate pathways related to antigen processing/presentation, human leukocyte antigens (HLA), and interferon responses across different cancer types on the transcriptomic level (Li et al., 2014; Wrangle et al., 2013). Nevertheless, these transcriptomic changes may not fully reflect the alterations of surface proteins that provoke susceptibility to immunotherapy. Thus, we sought to obtain a comprehensive profile of surface proteins altered by decitabine (DAC) through isolating cell surface proteins from A549 human lung cancer cells before and after DAC treatment using EZ-link Sulfo-NHS-SS-Biotin-assisted biotinylation method, followed by SILAC-based quantitative proteomics approach.
INSTRUMENT(S): LTQ Orbitrap
ORGANISM(S): Homo Sapiens (ncbitaxon:9606)
SUBMITTER: Hsing-Chen Tsai
PROVIDER: MSV000084997 | MassIVE | Fri Feb 21 11:03:00 GMT 2020
REPOSITORIES: MassIVE
ACCESS DATA